Wed. May 18th, 2022

MANILA — The Department of Justice has charged Rep. Janette Garin (Iloilo, 1st District) together with nine (9) others for alleged “reckless imprudence resulting to homicide over the controversial anti-Dengue vaccine Dengvaxia.”

In a prepared statement on riday, the DOJ said state prosecutors found probable cause to indict Garin, former Health secretary, and officials of the Department of Health, Food and Drug Administration, Research Institute for Tropical Medicine and Sanofi Pasteur Inc. for reckless imprudence resulting to homicide.

“The Panel [of prosecutors] concluded that the accomplishment of the procurement process for the Dengvaxia vaccine, with undue haste, within a limited timeframe, and despite the red flags known to Garin and other respondents, amounted to reckless imprudence,” DOJ said.

It was gathered state prosecutors also found Dengvaxia was allegedly purchased and dispensed for use although clinical trials for the anti-Dengue vaccine were yet to be finalized.

“The panel found that there was no showing that the Dengvaxia vaccine had undergone [World Health Organization] prequalification at the time the FDA issued the [Certificate of Product Registration,” the press release provided by Justice Assistant Secretary Neal Bainto said.

The prosecution went further in saying that that those accused did not fully inform, and obtain the consent of, those who were vaccinated and their families of the “nature and risks” of Dengvaxia.

The DOJ also said that state prosecutors indicted the president of Sanofi Pasteur for violating the Consumer Act of the Philippines “for manufacturing the Dengvaxia vaccine which poses certain risks to seronegatives, or to those who have not previously contracted the Dengue disease.”

“The Panel found that Sanofi indirectly admitted that Dengvaxia is a defective product due to the risk it poses to seronegatives,” it said.

The DOJ also stressed the vaccination was is in violation of Article 97 of Republic Act 7394 or the Consumer Act of the Philippines that holds that a product is defective if “it does not offer the safety rightfully expected of it,” including “the use and hazards reasonably expected of it.”

It may be recalled Health Secretary Francisco Duque III suspended the dengue vaccination program after Sanofi disclosed on Nov. 27, 2017 that it could cause severe dengue if given to those who had not previously been infected with dengue. (iamigo/

Leave a Reply